Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee, according to a July 22 news release.
The agreement adds Zilretta, an injectable osteoarthritis treatment, to Johnson & Johnson’s portfolio. The companies will also participate in shared professional education and initiatives to increase awareness of nonoperative care.
Zilretta is the first FDA-approved extended-release intra-articular therapy for patients with osteoarthritis-related knee pain. It uses a proprietary microsphere technology combining triamcinolone acetonide with a poly lactic-co-glycolic acid matrix.
